Cargando…

Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists

[Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Femke A., Doveston, Richard G., de Vries, Rens M.J.M., Vos, Gaël M., Vos, Alex A.A., Leysen, Seppe, Scheepstra, Marcel, Ottmann, Christian, Milroy, Lech-Gustav, Brunsveld, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956242/
https://www.ncbi.nlm.nih.gov/pubmed/31821760
http://dx.doi.org/10.1021/acs.jmedchem.9b01372
_version_ 1783487115408965632
author Meijer, Femke A.
Doveston, Richard G.
de Vries, Rens M.J.M.
Vos, Gaël M.
Vos, Alex A.A.
Leysen, Seppe
Scheepstra, Marcel
Ottmann, Christian
Milroy, Lech-Gustav
Brunsveld, Luc
author_facet Meijer, Femke A.
Doveston, Richard G.
de Vries, Rens M.J.M.
Vos, Gaël M.
Vos, Alex A.A.
Leysen, Seppe
Scheepstra, Marcel
Ottmann, Christian
Milroy, Lech-Gustav
Brunsveld, Luc
author_sort Meijer, Femke A.
collection PubMed
description [Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric inhibition. Here, we report a highly efficient in silico-guided approach that led to the discovery of novel allosteric RORγt inverse agonists with a distinct isoxazole chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment assay and effectively reduced IL-17a mRNA production in EL4 cells, a marker of RORγt activity. The projected allosteric mode of action of 25 was confirmed by biochemical experiments and cocrystallization with the RORγt ligand binding domain. The isoxazole compounds have promising pharmacokinetic properties comparable to other allosteric ligands but with a more diverse chemotype. The efficient ligand-based design approach adopted demonstrates its versatility in generating chemical diversity for allosteric targeting of RORγt.
format Online
Article
Text
id pubmed-6956242
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-69562422020-01-14 Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists Meijer, Femke A. Doveston, Richard G. de Vries, Rens M.J.M. Vos, Gaël M. Vos, Alex A.A. Leysen, Seppe Scheepstra, Marcel Ottmann, Christian Milroy, Lech-Gustav Brunsveld, Luc J Med Chem [Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric inhibition. Here, we report a highly efficient in silico-guided approach that led to the discovery of novel allosteric RORγt inverse agonists with a distinct isoxazole chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment assay and effectively reduced IL-17a mRNA production in EL4 cells, a marker of RORγt activity. The projected allosteric mode of action of 25 was confirmed by biochemical experiments and cocrystallization with the RORγt ligand binding domain. The isoxazole compounds have promising pharmacokinetic properties comparable to other allosteric ligands but with a more diverse chemotype. The efficient ligand-based design approach adopted demonstrates its versatility in generating chemical diversity for allosteric targeting of RORγt. American Chemical Society 2019-12-10 2020-01-09 /pmc/articles/PMC6956242/ /pubmed/31821760 http://dx.doi.org/10.1021/acs.jmedchem.9b01372 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Meijer, Femke A.
Doveston, Richard G.
de Vries, Rens M.J.M.
Vos, Gaël M.
Vos, Alex A.A.
Leysen, Seppe
Scheepstra, Marcel
Ottmann, Christian
Milroy, Lech-Gustav
Brunsveld, Luc
Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title_full Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title_fullStr Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title_full_unstemmed Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title_short Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
title_sort ligand-based design of allosteric retinoic acid receptor-related orphan receptor γt (rorγt) inverse agonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956242/
https://www.ncbi.nlm.nih.gov/pubmed/31821760
http://dx.doi.org/10.1021/acs.jmedchem.9b01372
work_keys_str_mv AT meijerfemkea ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT dovestonrichardg ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT devriesrensmjm ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT vosgaelm ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT vosalexaa ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT leysenseppe ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT scheepstramarcel ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT ottmannchristian ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT milroylechgustav ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists
AT brunsveldluc ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists